benzoxazoles has been researched along with mdl 100907 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, CE; Brennan, JA; Broqua, P; Feenstra, RW; Goutier, W; Graf, R; Grauer, SM; Hughes, ZA; Kruse, C; Lai, M; Lin, Q; Marquis, KL; McCreary, AC; Navarra, RL; Pausch, MH; Pruthi, F; Pulicicchio, CM; Robichaud, AJ; Rosenzweig-Lipson, S; Rotella, D; Smith, D; van de Neut, M; Wantuch, C | 1 |
1 other study(ies) available for benzoxazoles and mdl 100907
| Article | Year |
|---|---|
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzoxazoles; Brain; CHO Cells; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Drug Evaluation, Preclinical; Humans; Indenes; Male; Mice; Mice, Inbred Strains; Microdialysis; Motor Activity; Protein Binding; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D2; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Transfection | 2010 |